ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT)
Jae Duck Choi(Eulji University), Seong Il Seo(Samsung Medical Center)
Cited by 22
Related Papers
Clinicopathologic Characteristics and Prognosis of Xp11.2 Translocation Renal Cell Carcinoma: Multicenter, Propensity Score Matching Analysis
|Clinical Genitourinary Cancer|2017|24
Inhibition of PREX1 Reverses Enzalutamide Resistance in Castration-Resistant Prostate Cancer
|The World Journal of Men s Health|2025|1